Theorizing immune inhibition and TNF inhibitors from the autoimmune

Publication date

2022-03-16

Authors

Ben Shimon, OhadORCID 0000-0002-0161-9812ISNI 0000000517775897

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by_sa

Abstract

This article analyses the biochemical object of TNF inhibitors from the perspective of living with an autoimmune disease. The author tries to tease out how the concept of immune inhibition is used in tandem with the biochemical object of TNF inhibitors to dominate in defining and narrating what health and disease, normal and pathological, cure and healing can mean in the context of autoimmune bodies. Specifically, and within the 'pathological' framework of autoimmune diseases, the pharmacological treatment of TNF (tumour necrosis factor) inhibition is designed to suppress the 'overly' active immune system, thus acting as a negative or suppressing biochemical agent aimed at putting the 'malfunctioning' immune system back in balance. As can be seen in the current conjuncture, TNF inhibitors officially - and governmentally - place those tak-ing them in a risk group, as they 'lower' their overall bodily immunity and make them more vulnerable to infectious diseases, while stabilizing their patho-logical, 'over'-immune uninhibited condition. Part personal narrative of being diagnosed with an autoimmune condition, part speculative autoimmune theory inspired by such a diagnosis, the article ultimately calls for a different form of embodiment that is neither negative nor affirmative, and yet is resistant even to itself.

Keywords

TNF inhibitors, autoimmune, governmentality, immunity, inhibition, Philosophy, Social Sciences (miscellaneous), SDG 3 - Good Health and Well-being

Citation

Ben Shimon, O 2022, 'Theorizing immune inhibition and TNF inhibitors from the autoimmune', Recerca, vol. 27, no. 1. https://doi.org/10.6035/recerca.5767